Studies have reported that YAP, the major downstream effector of the Hippo pathway, is overexpressed in clinical tumor samples derived from pancreatic cancer patients and is a prognostic marker for metastatic pancreatic cancer [42,43]. Here, YAP1 is linked to familial pancreatic carcinoma.